Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.51 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16240125 | 1.00 | DPP4 (0.51) | DPP4DPP9GRM8GRM6GRIN2D | |
| SCHEMBL3353776 | 1.00 | DPP4 (0.51) | DPP4DPP9GRM8GRM6GRIN2D | |
| Trifluoroacetic Acid SCHEMBL3350406 | 0.91 | DPP4 (0.44) | DPP4DPP9GRM8GRM6GRIN2D | |
| SCHEMBL844868 | 0.89 | DPP4 (0.49) | DPP4DPP9GRM8GRM6GRIN2D | |
| SCHEMBL844867 | 0.89 | DPP4 (0.49) | DPP4DPP9GRM8GRM6GRIN2D | |
| SCHEMBL16240309 | 0.88 | DPP4 (0.47) | DPP4DPP9GRM8GRM6GRIN2D | |
| SCHEMBL16240308 | 0.88 | DPP4 (0.47) | DPP4DPP9GRM8GRM6GRIN2D | |
| SCHEMBL8913715 | 0.88 | DPP4 (0.47) | DPP4DPP9GRM8GRM6GRIN2D | |
| SCHEMBL7571298 | 0.86 | S1PR2 (0.48) | DPP4DPP9TDP1HSD17B10ALDH1A1 | |
| SCHEMBL6659262 | 0.86 | S1PR2 (0.48) | DPP4DPP9TDP1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| EP-2813558-B1 | GELLING AGENT | AJINOMOTO KK (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-9745339-B2 | Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-9522104-B2 | Gelling agent | AJINOMOTO CO., INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| EP-2812346-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | Graffinity Pharmaceuticals GmbH (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2813558-A1 | GELLING AGENT | Ajinomoto Co., Inc. (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140341960-A1 | GELLING AGENT | AJINOMOTO CO., INC. (JP) | 2014-11-20 | — | — | US | disclosed |
| WO-2014020152-A1 | LIGANDS FOR APHERESIS AND IMMUNOABSORPTION | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2013117707-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2013-08-15 | — | — | WO | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | DPP4 3895/4885DPP9 4385/4885GRM8 2289/4885 |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | DPP4 3808/4885DPP9 4344/4885GRM8 2262/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | DPP4 358/4885DPP9 2003/4885GRM8 948/4885 |
| US-20140341960-A1 | GELLING AGENT | CUTA, DEK, SUCLG1 | DPP4 3960/4885DPP9 3955/4885GRM8 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.